Current issues in dose-finding designs: A response to the US Food and Drug Adminstration’s Oncology Center of Excellence Project Optimus
Clinical Trials · 2024-06 · 21 (3) · 267-272
DOI: 10.1177/17407745241234652 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Trials, online erschienen am 03.04.2024. Verfasst von Peter F Thall und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Research Design, Antineoplastic Agents, Dose-Response Relationship, Drug. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Clinical Center.
Abstract (Originalsprache)
With the advent of targeted agents and immunological therapies, the medical research community has become increasingly aware that conventional methods for determining the best dose or schedule of a new agent are inadequate. It has been well established that conventional phase I designs cannot reliably identify safe and effective doses. This problem applies, generally, for cytotoxic agents, radiation therapy, targeted agents, and immunotherapies. To address this, the US Food and Drug Administration’s Oncology Center of Excellence initiated Project Optimus, with the goal “to reform the dose optimization and dose selection paradigm in oncology drug development.” As a response to Project Optimus, the articles in this special issue of Clinical Trials review recent advances in methods for choosing the dose or schedule of a new agent with an overall objective of informing clinical trialists of these innovative designs. This introductory article briefly reviews problems with conventional methods, the regulatory changes that encourage better dose optimization designs, and provides brief summaries of the articles that follow in this special issue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- American Society of Clinical Oncology, Alexandria, VA, USA.
- Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA.
- Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
- Department of Biostatistics, Columbia University, New York, NY, USA.
ORCID-Profile: Peter F Thall, Elizabeth Garrett-Mayer, Nolan A Wages, Susan Halabi
Förderung
- NCI NIH HHS
- Clinical Center
Zitieren
APA
Thall, P. F., Garrett-Mayer, E., Wages, N. A., Halabi, S., & Cheung, Y. K. (2024). Current issues in dose-finding designs: A response to the US Food and Drug Adminstration’s Oncology Center of Excellence Project Optimus. Clinical Trials, 21(3), 267-272. https://doi.org/10.1177/17407745241234652
Vancouver
Thall PF, Garrett-Mayer E, Wages NA, Halabi S, Cheung YK. Current issues in dose-finding designs: A response to the US Food and Drug Adminstration’s Oncology Center of Excellence Project Optimus. Clinical Trials. 2024;21(3):267-272. doi:10.1177/17407745241234652
BibTeX
@article{Thall2024,
author = {Thall, Peter F and Garrett-Mayer, Elizabeth and Wages, Nolan A and Halabi, Susan and Cheung, Ying Kuen},
title = {Current issues in dose-finding designs: A response to the US Food and Drug Adminstration’s Oncology Center of Excellence Project Optimus},
journal = {Clinical Trials},
year = {2024},
volume = {21},
number = {3},
pages = {267--272},
doi = {10.1177/17407745241234652}
}
EUVIMED